S1PR3 and multiple sclerosis: While drug development has prioritized S1P1 receptors—spurred by the non-specific S1P receptor agonist fingolimod (approved by the FDA in 2010 and EMA in 2011 for multiple sclerosis [37])—S1PR3’s established angiogenic role [13] positions it as a compelling candidate for therapeutic exploitation.